Oaklander welcomed the news of the approval of the new vaccine, saying that more adults should be vaccinated against shingles. In the United States alone, there are an estimated 1 million cases of shingles a year, and one in three people can expected to develop the condition during their lifetime.
6 brokerages have issued twelve-month price objectives for Arbutus Biopharma Corp's shares. Their forecasts range from $5.00 to $10.00. On average, they anticipate Arbutus Biopharma Corp's stock price to reach $7.00 in the next year.
MarketWatch News on FCSC. 1  Fibrocell Science stock price target cut to $4 from $6 at Wedbush Securities. 8:29 a.m. March 11, 2016. 2  Fibrocell Science downgraded to neutral from outperform at Wedbush Securities. 12:11 p.m. 3  Drug stocks mixed after Fed statement. 2:02 p.m. June 22, 2011.